Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Contact
103 Carnegie Center Drive
Suite 300
PrincetonNJ08852
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.60 | 17.60 | 0.20% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,656.25 | 406.96 | 1.68% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,077.14 | 1,859.87 | 2.90% |
| NZX 50 Index | 13,393.87 | 191.71 | 1.45% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,792.30 | 18.80 | 0.21% |
| SSE Composite Index | 4,042.76 | 55.75 | 1.40% |